Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: A phase II study

Clinical Nuclear Medicine

Volumn 38, Issue 2, 2013, Pages 88-92

  Yuan, Jie ^a   Liu, Congjin ^a   Liu, Xingdang ^a   Wang, Yuankai ^a   Kuai, Dayu ^a   Zhang, Guangming ^a   Zaknun, John J ^b  

^a FUDAN UNIVERSITY   (China)

^b INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

177Lu EDTMP; osseous metastases; phase II study; radiopharmaceutical therapy bone pain

Indexed keywords

ANALGESIC AGENT; HEMOGLOBIN; RADIOPHARMACEUTICAL AGENT; THYMIDINE PHOSPHATE LU 177; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; PAIN ASSESSMENT; PATIENT MOBILITY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HORMONES; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SAFETY; TREATMENT FAILURE;

EID: 84872974331     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318279bf4d     Document Type: Article

References (21)

1. Papachristou DJ, Basdra EK, Papavassiliou AG. Bone metastases: Molecular mechanisms and novel therapeutic interventions. Med Res Rev. 2012;32:611-636
2. Barnes EA. Radiopharmaceuticals for painful bone metastases: Perspective from radiation oncology. J Support Oncol. 2011;9:208-209
3. Fischer M, Kampen WU. Radionuclide therapy of bone metastases. Breast Care (Basel). 2012;7:100-107
4. Christensen MH, Petersen LJ. Radionuclide treatment of painful bone metastases in patients with breast cancer: A systematic review. Cancer Treat Rev. 2012;38:164-171
5. Horwich A, Parker C, Kataja V. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(suppl 4): 76-78
6. Shah Syed GM, Maken RN, Muzzaffar N, et al. Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nucl Med Commun. 1999;20:697-702 (Pubitemid 29507688)
7. Fang N, Li Y, Xu YS, et al. Serum concentrations of IL-2 and TNF-Alpha in patients with painful bone metastases: Correlation with responses to (SrCl2)-Sr-89 therapy. J Nucl Med. 2006;47:242-246 (Pubitemid 46780888)
8. Maini CL, Bergomi S, Romano L, et al. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1): S171YS178 (Pubitemid 38833047)
9. Sola G, Arguelles MG, Bottazzini DL, et al. Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and pre-clinical studies. Radiochim Acta. 2000;88:157-161
10. Chakraborty S, Das T, Banerjee S, et al. (177)Lu-EDTMP: A viable bone pain palliative in skeletal metastasis. Cancer Biother Radio. 2008;23:202-213 (Pubitemid 351630191)
11. Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med. 2001;8:1153-1157 (Pubitemid 33108207)
12. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A:1135-1141
13. Liu C, Brasic JR, Liu X, et al. Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment. Nucl Med Commun. 2012;33:90-96
14. Das T, Chakraborty S, Unni PR, et al. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot. 2002;57:177-184 (Pubitemid 34607654)
15. Chakraborty S, Das T, Unni PR, et al. Lu-177 labelled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun. 2002;23: 67-74 (Pubitemid 34214308)
16. Ando A, Ando I, Tonami N, et al. Lu-177-EDTMP: A potential therapeutic bone agent. Nucl Med Commun. 1998;19:587-591 (Pubitemid 28319780)
17. Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007;28:623-630 (Pubitemid 47067049)
18. Nishio M, Sano M, Tamaki Y, et al. A multicenter study to determine the efficacy and safety of strontium (89Sr) chloride for palliation of painful bony metastases in cancer patients [in Japanese]. Nihon Igaku Hoshasen Gakkai Zasshi. 2005;65:399-410 (Pubitemid 41772438)
19. Chuvilin DY, Khvostionov VE, Markovskij DV, et al. Production of 89Sr in solution reactor. Appl Radiat Isot. 2007;65:1087-1094
20. Ratsimanohatra H, Barlesi F, Doddoli C, et al. Use of 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer. Rev Mal Respir. 2005;22:317-320 (Pubitemid 40676364)
21. Tripathi M, Singhal T, Chandrasekhar N, et al. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer. 2006;43:86-92 (Pubitemid 43988308)